I'm about 4.5 years into the trial, on Dasatinib and the availability of Dasatinib on the trial protocol ends in around March 2018, the 5 year anniversary of the last enrolled patient.
It has been a concern of mine for some time that there has been no statement about what happens to Dasatinb availability post-trial: Bristol Myers Squibb refused to respond to me, citing a requirement that I only deal with my consultants, and my consultants said they did not have any information either from the NHS or BMS - stalemate!
However this week, after some hassling, I got the email below forwarded by Kings College Hospital direct from the Spirit 2 trials office: it would appear that NHSE have considered the plight of the hundreds of Spirit 2 Dasatinib arm patients and agreed to continue to supply Dasatinib. Good news for anyone else who had concerns!
Rod
============================================================================
From: Corinne Hedgley <c.a.hedgley@newcastle.ac.uk>
Sent: 30 August 2016 09:30
To: Emin Hassan Natasha (KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST)
Cc: Mihir Vaghela
Subject: RE: RM end of trial query
Dear Natasha,
Many thanks for your email.
I can confirm that dasatinib will continue to be supplied free of charge to patients randomised to the dasatinib arm until 5 years after the last patient recruited (this will be March 2018). After this time patients will be able to access dasatinib from the NHS. NHSE are aware of the SPIRIT 2 study and have confirmed that patients who were randomised to receive dasatinib via SPIRIT 2 will continue to be able to receive it after the end of the study.
With best wishes
Corinne
_______________________________
Corinne Hedgley
Senior Trial Manager
NCTU
Northern Institute for Cancer Research
International Centre for Life
Newcastle University
NE1 4EP
Tel: +44 191 282 0904
Fax: +44 191 376 0748
Email: c.a.hedgley@ncl.ac.uk
Website: www.spirit-cml.org
